Fresenius Medical Care delivers 27% earnings growth in 2025 and reaches upper end of its financial outlook; margin within 2025 mid-term target band

Core Insights - Fresenius Medical Care achieved a 27% growth in operating income for 2025, reaching the upper end of its financial outlook, with a significant margin increase to 11.3% [1][2][3] - The company plans to propose a dividend of EUR 1.49 per share, reflecting a 3% increase, and has executed an accelerated share buyback program [1][2] - The FME Reignite strategy is set to enhance operational efficiency and profitability, with expectations of 3-7% CAGR in operating income through 2028 [1][3] Financial Performance - In Q4 2025, revenue was EUR 5,070 million, stable year-on-year, with a 7% increase at constant currency and 8% organic growth [2][3] - Full-year revenue for 2025 increased by 2% to EUR 19,628 million, with organic growth of 8% [2][3] - Operating income for Q4 2025 surged by 129% to EUR 594 million, resulting in a margin of 11.7% [2][3] - Full-year operating income rose by 31% to EUR 1,827 million, achieving a margin of 9.3% [2][3] Strategic Developments - The FME25+ transformation program delivered EUR 238 million in sustainable savings for 2025, exceeding the target of EUR 220 million [1][2] - Fresenius Medical Care is focusing on portfolio optimization, exiting non-core assets, which negatively impacted revenue by EUR 244 million in 2025 [1][2] - The company is set to launch the 5008X CAREsystem for high-volume hemodiafiltration in the U.S. in 2026, with significant investments in training and patient transitions [1][3] Shareholder Returns - The new capital allocation framework aims for a stable dividend payout ratio of 30% to 40% of net income, with a planned dividend of EUR 1.49 per share for 2025 [1][2] - A share buyback program of EUR 1 billion is currently underway, with the first tranche completed by December 2025 [1][2] Outlook - For 2026, Fresenius Medical Care anticipates flat revenue growth and stable operating income, with a mid-single-digit growth rate expected [3][4] - The company aims for a CAGR of 3-7% in operating income from 2025 to 2028 and aspires to achieve a mid-teens percent operating income margin by 2030 [3][4]